A single nucleotide polymorphism in CYP1B1 leads to differential prostate cancer risk and telomere length

作者：Gu, Cheng-Yuan; Li, Gao-Xiang; Zhu, Yu; Xu, Hua; Zhu, Yao; Qin, Xiao-Jian; Bo, Dai^*; Ye, Ding-Wei^*

来源：Journal of Cancer, 2018, 9(2): 269-274.

DOI：10.7150/jca.21774

• CYP1B1
• prostate cancer
• single nucleotide polymorphism
• susceptibility

BACKGROUND: Cytochrome P450 1B1 (CYP1B1) is a key enzyme in its oestrogen metabolism pathway, giving rise to hydroxylation and conjugation. Functionally relevant genetic variants within CYP1B1 may affect the telomere length and subsequently lead to prostate carcinogenesis. @@@ METHODS: We evaluated 8 CYP1B1 tag single nucleotide polymorphisms (SNPs) in 1015 men with prostate cancer (PCa) and 1052 cancer-free controls, and calculated odds ratios (ORs) and 95% confidence intervals (CIs) to estimate their association with risk of PCa. The influence of CYP1B1 SNPs on the relative telomere lengths was then appraised in peripheral blood leukocytes using real-time PCR. @@@ RESULTS: CYP1B1 rs1056836 variant was associated with decreased risk of PCa [odds ratio (OR): 0.80; 95% confidence interval (CI): 0.68-0.99, P = 0.041]. Longer telomere length showed a significantly higher proportion of the CYP1B1 rs1056836 CG/GG genotypes, compared with that of the CC genotype (OR: 1.60, 95% CI: 1.04-2.45). @@@ CONCLUSION: Our findings suggest that genetic variants within CYP1B1 may confer genetic susceptibility to PCa by altering telomere length.

• 出版日期2018
• 单位复旦大学